IFNG and cancer: Considering that SLAMF7 is a target in cancer therapy,31 its epigenetic regulation in Th1 cells and differential expression in IFN‐γ producing memory CD4+ T cells encouraged us to take a closer look at the SLAMF7 expression at the protein level in TCR‐triggered CD4+ T cells.